Immunic posts investor overview presentation on multiple sclerosis strategy

• Immunic published an investor overview highlighting vidofludimus calcium (IMU-838) as an oral multiple sclerosis therapy with dual Nurr1 activation, selective DHODH inhibition.
• Phase 3 ENSURE-1, ENSURE-2 trials in relapsing MS fully enrolled; top-line results expected by end of 2026.
• U.S. NDA submission targeted for mid-2027; potential U.S. approval anticipated in 2028.
• Phase 2 CALLIPER in progressive MS showed numerical reductions in confirmed disability worsening, signals for disability improvement; Phase 3 program in preparation.
• Funding expected into late 2027; intellectual property protection expected up to 2044 in the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.